The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Result of phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small cell lung cancer.
Yan Sun
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Xuezhi Hao
No relevant relationships to disclose
Jie Wang
No relevant relationships to disclose
Chengping Hu
No relevant relationships to disclose
Baohui Han
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Li Zhang
No relevant relationships to disclose
Huiping Wan
No relevant relationships to disclose
Zhongjun Xia
No relevant relationships to disclose
Yunpeng Liu
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Mei Hou
No relevant relationships to disclose
Helong Zhang
No relevant relationships to disclose
Qingyu Xiu
No relevant relationships to disclose
Yunzhong Zhu
No relevant relationships to disclose
Jifeng Feng
No relevant relationships to disclose
Shukui Qin
No relevant relationships to disclose